An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains.
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains.
The BRCA patents, which claim breast cancer diagnostic methods and BRCA DNA molecules, have courted significant controversy in Australia. Specifically, the Australian licensee’s attempt to centralise BRCA diagnostic testing in-house caused great public concern and triggered the establishment of a Senate enquiry into the impact of granting gene patents.
This enquiry was followed by the introduction of legislation proposing to ban the patenting of all biological materials that are identical or substantially identical to such materials as they exist in nature, and itself led to the establishment of a second Senate enquiry to report on whether the Bill should be pursued. The validity of the Australian BRCA DNA claims is also currently the subject of judicial revocation proceedings.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
gene patents, Australia Patents Act, biotechnology
